Prime Medicine said Friday it successfully used a new, ultra-versatile form of genetic surgery called prime editing to edit liver cells in monkeys.
The results, presented at the European Society of Gene & Cell Therapy meeting in Brussels, are a major step for a technology that could transform treatment of numerous diseases.
advertisement
“I think the big celebration here is we’re showing, in primates, for the company, that we have a delivery system that is working and is safe,” said Jeremy Duffield, Prime’s chief scientific officer.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
PhRMA sues HHS over Medicare drug price negotiation
Next article： Drug repurposing or repositioning? The language matters
Next article： Drug repurposing or repositioning? The language matters
